Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

80%(4 trials)

Phase Distribution

Ph phase_3

50%

Ph phase_2

33%

Ph phase_1

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

2(33.3%)

Phase 3Large-scale testing

3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Detailed Status

Completed5

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (16.7%)

Phase 22 (33.3%)

Phase 33 (50.0%)

Trials by Status

completed583%

withdrawn117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_3

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780

completedphase_3

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767

completedphase_3

RESCUE and REVERSE Long-term Follow-up

NCT03406104

completedphase_1

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

NCT03397264

withdrawnphase_2

Combined Ranibizumab and Iluvien for Diabetic Macular Oedema

NCT03784443

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT02652780Phase 3

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

Completed

NCT02652767Phase 3

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

Completed

NCT03406104Phase 3

RESCUE and REVERSE Long-term Follow-up

Completed

NCT03397264Phase 1

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

Completed

NCT03784443Phase 2

Combined Ranibizumab and Iluvien for Diabetic Macular Oedema

Withdrawn

NCT03345082Phase 2

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Completed

All 6 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 6